171 related articles for article (PubMed ID: 36261215)
1. Intradermal vaccination of HPV-16 E6 synthetic peptides conjugated to an optimized Toll-like receptor 2 ligand shows safety and potent T cell immunogenicity in patients with HPV-16 positive (pre-)malignant lesions.
Speetjens FM; Welters MJP; Slingerland M; van Poelgeest MIE; de Vos van Steenwijk PJ; Roozen I; Boekestijn S; Loof NM; Zom GG; Valentijn ARPM; Krebber WJ; Meeuwenoord NJ; Janssen CAH; Melief CJM; van der Marel GA; Filippov DV; van der Burg SH; Gelderblom H; Ossendorp F
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36261215
[TBL] [Abstract][Full Text] [Related]
2. Enhanced HPV16 E6/E7
Stegmann T; Wiekmeijer AS; Kwappenberg K; van Duikeren S; Bhoelan F; Bemelman D; Beenakker TJM; Krebber WJ; Arens R; Melief CJM
Cancer Immunol Immunother; 2023 Aug; 72(8):2851-2864. PubMed ID: 37222770
[TBL] [Abstract][Full Text] [Related]
3. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity.
Kenter GG; Welters MJ; Valentijn AR; Lowik MJ; Berends-van der Meer DM; Vloon AP; Drijfhout JW; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; van der Burg SH; Melief CJ
Clin Cancer Res; 2008 Jan; 14(1):169-77. PubMed ID: 18172268
[TBL] [Abstract][Full Text] [Related]
4. Novel TLR2-binding adjuvant induces enhanced T cell responses and tumor eradication.
Zom GG; Willems MMJHP; Khan S; van der Sluis TC; Kleinovink JW; Camps MGM; van der Marel GA; Filippov DV; Melief CJM; Ossendorp F
J Immunother Cancer; 2018 Dec; 6(1):146. PubMed ID: 30541631
[TBL] [Abstract][Full Text] [Related]
5. TLR2 ligand-synthetic long peptide conjugates effectively stimulate tumor-draining lymph node T cells of cervical cancer patients.
Zom GG; Welters MJ; Loof NM; Goedemans R; Lougheed S; Valentijn RR; Zandvliet ML; Meeuwenoord NJ; Melief CJ; de Gruijl TD; Van der Marel GA; Filippov DV; Ossendorp F; Van der Burg SH
Oncotarget; 2016 Oct; 7(41):67087-67100. PubMed ID: 27564262
[TBL] [Abstract][Full Text] [Related]
6. Polymeric nanoparticles for co-delivery of synthetic long peptide antigen and poly IC as therapeutic cancer vaccine formulation.
Rahimian S; Fransen MF; Kleinovink JW; Christensen JR; Amidi M; Hennink WE; Ossendorp F
J Control Release; 2015 Apr; 203():16-22. PubMed ID: 25660830
[TBL] [Abstract][Full Text] [Related]
7. HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial.
van Poelgeest MI; Welters MJ; van Esch EM; Stynenbosch LF; Kerpershoek G; van Persijn van Meerten EL; van den Hende M; Löwik MJ; Berends-van der Meer DM; Fathers LM; Valentijn AR; Oostendorp J; Fleuren GJ; Melief CJ; Kenter GG; van der Burg SH
J Transl Med; 2013 Apr; 11():88. PubMed ID: 23557172
[TBL] [Abstract][Full Text] [Related]
8. A phase 1, single centre, open label, escalating dose study to assess the safety, tolerability and immunogenicity of a therapeutic human papillomavirus (HPV) DNA vaccine (AMV002) for HPV-associated head and neck cancer (HNC).
Chandra J; Woo WP; Finlayson N; Liu HY; McGrath M; Ladwa R; Brauer M; Xu Y; Hanson S; Panizza B; Frazer IH; Porceddu SV
Cancer Immunol Immunother; 2021 Mar; 70(3):743-753. PubMed ID: 32918586
[TBL] [Abstract][Full Text] [Related]
9. The long-term immune response after HPV16 peptide vaccination in women with low-grade pre-malignant disorders of the uterine cervix: a placebo-controlled phase II study.
de Vos van Steenwijk PJ; van Poelgeest MI; Ramwadhdoebe TH; Löwik MJ; Berends-van der Meer DM; van der Minne CE; Loof NM; Stynenbosch LF; Fathers LM; Valentijn AR; Oostendorp J; Osse EM; Fleuren GJ; Nooij L; Kagie MJ; Hellebrekers BW; Melief CJ; Welters MJ; van der Burg SH; Kenter GG
Cancer Immunol Immunother; 2014 Feb; 63(2):147-60. PubMed ID: 24233343
[TBL] [Abstract][Full Text] [Related]
10. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
[TBL] [Abstract][Full Text] [Related]
11. Photochemical Internalization Enhanced Vaccination Is Safe, and Gives Promising Cellular Immune Responses to an HPV Peptide-Based Vaccine in a Phase I Clinical Study in Healthy Volunteers.
Otterhaug T; Janetzki S; Welters MJP; Håkerud M; Nedberg AG; Edwards VT; Boekestijn S; Loof NM; Selbo PK; Olivecrona H; van der Burg SH; Høgset A
Front Immunol; 2020; 11():576756. PubMed ID: 33488576
[TBL] [Abstract][Full Text] [Related]
12. Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses.
Welters MJ; Kenter GG; de Vos van Steenwijk PJ; Löwik MJ; Berends-van der Meer DM; Essahsah F; Stynenbosch LF; Vloon AP; Ramwadhdoebe TH; Piersma SJ; van der Hulst JM; Valentijn AR; Fathers LM; Drijfhout JW; Franken KL; Oostendorp J; Fleuren GJ; Melief CJ; van der Burg SH
Proc Natl Acad Sci U S A; 2010 Jun; 107(26):11895-9. PubMed ID: 20547850
[TBL] [Abstract][Full Text] [Related]
13. Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response.
van Poelgeest MI; Welters MJ; Vermeij R; Stynenbosch LF; Loof NM; Berends-van der Meer DM; Löwik MJ; Hamming IL; van Esch EM; Hellebrekers BW; van Beurden M; Schreuder HW; Kagie MJ; Trimbos JB; Fathers LM; Daemen T; Hollema H; Valentijn AR; Oostendorp J; Oude Elberink JH; Fleuren GJ; Bosse T; Kenter GG; Stijnen T; Nijman HW; Melief CJ; van der Burg SH
Clin Cancer Res; 2016 May; 22(10):2342-50. PubMed ID: 26813357
[TBL] [Abstract][Full Text] [Related]
14. GTL001, A Therapeutic Vaccine for Women Infected with Human Papillomavirus 16 or 18 and Normal Cervical Cytology: Results of a Phase I Clinical Trial.
Van Damme P; Bouillette-Marussig M; Hens A; De Coster I; Depuydt C; Goubier A; Van Tendeloo V; Cools N; Goossens H; Hercend T; Timmerman B; Bissery MC
Clin Cancer Res; 2016 Jul; 22(13):3238-48. PubMed ID: 27252412
[TBL] [Abstract][Full Text] [Related]
15. GTL001 and bivalent CyaA-based therapeutic vaccine strategies against human papillomavirus and other tumor-associated antigens induce effector and memory T-cell responses that inhibit tumor growth.
Esquerré M; Momot M; Goubier A; Gonindard C; Leung-Theung-Long S; Misseri Y; Bissery MC
Vaccine; 2017 Mar; 35(11):1509-1516. PubMed ID: 28196735
[TBL] [Abstract][Full Text] [Related]
16. Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses.
Welters MJ; van der Sluis TC; van Meir H; Loof NM; van Ham VJ; van Duikeren S; Santegoets SJ; Arens R; de Kam ML; Cohen AF; van Poelgeest MI; Kenter GG; Kroep JR; Burggraaf J; Melief CJ; van der Burg SH
Sci Transl Med; 2016 Apr; 8(334):334ra52. PubMed ID: 27075626
[TBL] [Abstract][Full Text] [Related]
17. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia.
Kenter GG; Welters MJ; Valentijn AR; Lowik MJ; Berends-van der Meer DM; Vloon AP; Essahsah F; Fathers LM; Offringa R; Drijfhout JW; Wafelman AR; Oostendorp J; Fleuren GJ; van der Burg SH; Melief CJ
N Engl J Med; 2009 Nov; 361(19):1838-47. PubMed ID: 19890126
[TBL] [Abstract][Full Text] [Related]
18. HPV-16 E6/E7 DNA tattoo vaccination using genetically optimized vaccines elicit clinical and immunological responses in patients with usual vulvar intraepithelial neoplasia (uVIN): a phase I/II clinical trial.
Bakker NAM; Rotman J; van Beurden M; Zijlmans HJM; van Ruiten M; Samuels S; Nuijen B; Beijnen J; De Visser K; Haanen J; Schumacher T; de Gruijl TD; Jordanova ES; Kenter GG; van den Berg JH; van Trommel NE
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34341131
[TBL] [Abstract][Full Text] [Related]
19. Vaccination with human papillomavirus pseudovirus-encapsidated plasmids targeted to skin using microneedles.
Kines RC; Zarnitsyn V; Johnson TR; Pang YY; Corbett KS; Nicewonger JD; Gangopadhyay A; Chen M; Liu J; Prausnitz MR; Schiller JT; Graham BS
PLoS One; 2015; 10(3):e0120797. PubMed ID: 25785935
[TBL] [Abstract][Full Text] [Related]
20. Vaccination with synthetic long peptide formulated with CpG in an oil-in-water emulsion induces robust E7-specific CD8 T cell responses and TC-1 tumor eradication.
Maynard SK; Marshall JD; MacGill RS; Yu L; Cann JA; Cheng LI; McCarthy MP; Cayatte C; Robbins SH
BMC Cancer; 2019 Jun; 19(1):540. PubMed ID: 31170937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
